Cart
sales@molnova.com
AD57
CAS No. 1093380-42-7
AD57( —— )
Catalog No. M33828 CAS No. 1093380-42-7
AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 90 | In Stock |
|
| 2MG | 32 | In Stock |
|
| 5MG | 79 | In Stock |
|
| 10MG | 148 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 351 | In Stock |
|
| 100MG | 476 | In Stock |
|
| 200MG | 644 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAD57
-
NoteResearch use only, not for human use.
-
Brief DescriptionAD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
-
DescriptionAD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetSrc
-
RecptorSrc | Bcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1093380-42-7
-
Formula Weight455.44
-
Molecular FormulaC22H20F3N7O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (274.46 mM; Ultrasonic )
-
SMILESCC(C)n1nc(-c2ccc(NC(=O)Nc3cccc(c3)C(F)(F)F)cc2)c2c(N)ncnc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012 Jun 6;486(7401):80-4. ?
molnova catalog
related products
-
Saracatinib
A potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively.
-
WAY-303290
WAY-303290 inhibits the pY binding site of tyrosine kinase p56lck SH2 domain.
-
CpCDPK1/TgCDPK1-IN-1
CpCDPK1/TgCDPK1-IN-1 is a potent dual inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections and cryptosporidiosis.
